89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 21 2020 - 4:05PM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced that Rohan Palekar, the
company’s Chief Executive Officer, will present at the SVB Leerink
9th Annual Global Healthcare Conference on Wednesday, February 26,
2020 at 11:30 AM ET in New York, NY.
The live and archived webcast of the
presentation will be accessible from the company’s website at
https://ir.89bio.com/events-and-presentations. The replay of the
webcast will be available on the company’s website.
About 89bio89bio is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of innovative therapies for the treatment of
liver and cardio-metabolic diseases. The company’s lead product
candidate, BIO89-100, is being developed for the treatment of NASH.
The company also intends to develop BIO89-100 for the treatment of
SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog
of FGF21 that is currently in a proof of concept Phase 1b/2a
clinical trial in patients with NASH or NAFLD and a high risk of
NASH. 89bio is headquartered in San Francisco with operations in
Herzliya, Israel. Visit 89bio.com for more information.
Forward-Looking
StatementsCertain statements in this press release may
constitute "forward-looking statements" within the meaning of the
federal securities laws, including, but not limited to, 89bio’s
expectations regarding plans for its clinical programs and clinical
studies. Words such as “may,” “might,” “will,” “objective,”
“intend,” “should,” “could,” “can,” “would,” “expect,” “believe,”
“design,” “estimate,” “predict,” “potential,” “develop,” “plan” or
the negative of these terms, and similar expressions, or statements
regarding intent, belief, or current expectations, are
forward-looking statements. While 89bio believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties
(including, without limitation, those set forth in 89bio’s filings
with the U.S. Securities and Exchange Commission (SEC)), many of
which are beyond 89bio’s control and subject to change. Actual
results could be materially different. Risks and uncertainties
include: expectations regarding the enrollment, completion and
outcome of 89bio’s proof of concept Phase 1b/2a clinical trial
evaluating BIO89-100 in patients with NASH or patients with NAFLD
and a high risk of NASH; expectations regarding the development of
BIO89-100 for SHTG and the related Phase 2 study; the unpredictable
relationship between preclinical study results and clinical study
results; liquidity and capital resources; and other risks and
uncertainties identified in 89bio’s filings with the SEC. 89bio
expressly disclaims any obligation to update or alter any
statements whether as a result of new information, future events or
otherwise, except as required by law.
Investor Contact: Ryan Martins Chief Financial Officer
investors@89bio.com
Media Contact: Lori Rosen LDR Communications 917-553-6808
lori@ldrcommunications.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2024 to May 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From May 2023 to May 2024